FDA Inspection 1193294 — Blueprint Medicines Corporation

Blueprint Medicines Corporation — FEI 3011881091

The FDA completed an inspection of Blueprint Medicines Corporation on Nov 18, 2022 in Cambridge, MA. The inspection was classified NAI (No Action Indicated — no objectionable conditions or practices were found during the inspection). Product area: Drugs.

Inspection details

Classification
No Action Indicated (NAI)
End Date
Nov 18, 2022
Fiscal Year
2023
Product Type
Drugs
Project Area
Bioresearch Monitoring
Location
Cambridge, MA (United States)

Additional details

Postmarket Adverse Drug Experience (PADE)

Sources: openFDA, FDA Data Dashboard, FDA.gov. Report a data issue: hello@regdatalab.com.